Drug intelligence / Profile preview

601

Development stage: Phase 3
Lead developer: 3S Guojian Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal Injection

Overview

601 is a recombinant humanized anti-VEGF monoclonal antibody developed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. It is being investigated for the treatment of various ocular conditions characterized by abnormal vascular growth and leakage, including macular edema secondary to Branch Retinal Vein Occlusion (BRVO), pathological myopic choroidal neovascularization (pmCNV), macular edema secondary to Central Retinal Vein Occlusion (CRVO), wet Age-related Macular Degeneration (wAMD), and Diabetic Macular Edema (DME).

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on 601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 601.

Explore the full profile